InsiderTrades

Form 4 for KNSA Kiniksa Pharmaceuticals International, plc

Accepted 2025-11-14 00:00:00 ET · period of report 2025-11-12 · accession 0001835458-25-000005 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X Filed Traded Ticker Insider Title Type Price Qty Owned ΔOwn Value
D 2025-11-14 2025-11-12 KNSA Ragosa Mark CFO M - OptEx $30.93 +19.9K 51.0K +64% +$615.5K
D 2025-11-14 2025-11-12 KNSA Ragosa Mark CFO S - Sale+OE $40.94 -19.9K 31.1K -39% -$814.7K
D 2025-11-14 2025-11-12 KNSA Ragosa Mark CFO M - OptEx $0.00 -19.9K 0 -100% $0

Purchase Sale Sale after option exercise All abbreviations

Every reported transaction

#TableSecurityDateCodeA/DSharesPriceOwned afterOwnExercise / expiryUnderlyingFootnotes
1 Common Class A Ordinary Share 2025-11-12 M A 19,900 $30.93 50,986 D — —
2 Common Class A Ordinary Share 2025-11-12 S D 19,900 $40.94 31,086 D — — (F2) This transaction was executed in multiple trades through a broker-dealer at prices ranging between $40.93 and $41.035. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.
3 Derivative Share Option 2025-11-12 M D 19,900 $0.00 0 D $30.93 · — to 2028-09-19 19,900 Class A Ordinary Share (F3) The option is fully vested and exercisable.